Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

NCT02985879 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02985879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02985879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
December 12, 2016
Completion date
November 20, 2019
Enrollment
378 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy